Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FOLR1 positive status confers therapeutic sensitivity to Mirvetuximab soravtansine in patients with Peritoneal Serous Carcinoma.
This statement is based on a regulatory approval from the European Medicines Agency:
ELAHERE as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FDalpha) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.